Establishment of a Tumor Bank for Blood Samples

March 21, 2023 updated by: Robert Zeillinger, Dr.phil., Medical University of Vienna

Establishment of a Blood Sample Bank in the Field of Gynaecological Oncology.

Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. The relevance of "translational oncology" will only increase in the future -"From bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient.

Its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research.

The aim of this tumor bank is to consist of biological samples (together with a tissue bank - see EK 260/2003) and isolates of tumor patients and healthy people as controls. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. The content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).

Study Type

Observational

Enrollment (Anticipated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Austria
      • Innsbruck, Austria, 6020
        • Completed
        • Innsbruck Medical University
  • Belgium
      • Leuven, Belgium, 3000
        • Completed
        • University Hospitals Leuven - Department of Obstetrics and Gynaecology
  • Germany
      • Berlin, Germany, 13353
        • Recruiting
        • Charité University - Campus Virchow Chlinic
        • Contact:
        • Contact:
          • Ioana Braicu, Dr.
          • Phone Number: 002 +49 30 450 564
          • Email: ioana@braicu.de
      • Freiburg, Germany, 79106
        • Completed
        • University Medical Center Freiburg
      • Herne, Germany, 44626
        • Completed
        • University Clinic of Ruhr University Bochum
  • Italy
      • Milan, Italy, 20100
        • Withdrawn
        • European Institute of Oncology, Division of Gynecologic Oncology, Unit of Preventive Gynecology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  • Male and female patients/people.
  • Minimum age 18 years
  • Characteristics: Recruited at the Medical University Vienna or at one of the facilities cooperating with the Vienna Med. University

Description

Inclusion Criteria:

  • Male/Female
  • Age 18 to 90 years max.
  • Just one current known malignant disease or
  • Just one current inflammatory disease

Exclusion Criteria:

  • Inflammatory disease and malignant disease
  • multiple malignancies
  • multiple diseases
  • underage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Malignant tumors
Patients who have one of the Neoplasms stated above under "conditions". Blood samples will be taken.
Other: Blood collection
Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
Benign controls

Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.

Blood samples will be taken.
Other: Blood collection
Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
Healthy controls

People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.

Blood samples will be taken.
Other: Blood collection
Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.
Time Frame: 14 years
14 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Vienna

Investigators

  • Principal Investigator: Robert Zeillinger, Prof.Dr., Medical University Vienna, Dept. of Obstetrics & Gynaecology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2003

Primary Completion (Anticipated)

December 1, 2026

Study Completion (Anticipated)

December 1, 2026

Study Registration Dates

First Submitted

January 4, 2013

First Submitted That Met QC Criteria

January 7, 2013

First Posted (Estimate)

January 8, 2013

Study Record Updates

Last Update Posted (Actual)

March 23, 2023

Last Update Submitted That Met QC Criteria

March 21, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EK 366/2003

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endocrine Gland Neoplasms

Clinical Trials on Blood collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe